A phase 1b/2, master protocol evaluating the safety, tolerability, pharmacokinetics, and efficacy of sotorasib (AMG 510) in subjects with advanced solid tumors with KRAS p.G12C Mutation (CodeBreaK 101)

UVA Tracking #
HSR220237
Principal Investigator
Ryan Gentzler
Contact
Contact Phone
Official Trial Title
A phase 1b/2, master protocol evaluating the safety, tolerability, pharmacokinetics, and efficacy of sotarasib (AMG 510) in subjects with advanced solid tumors with KRAS p.G12C Mutation
Study Description

The University of Virginia Cancer Center is conducting a clinical research study for patients who are adults ages 18 and over, and have a KRAS pG12C mutation in lung or colorectal cancer. The purpose of this study to evaluate an investigational drug, sotorasib in combination with chemotherapies or another investigational drug. The safety and effects of the investigational treatment will be assessed for this study.

Participation includes a screening period, treatment cycles of 3-4 weeks with sotorasib (taken by mouth daily) plus chemotherapy and/or additional investigational drugs, and a longer term follow-up via a clinic visit or a phone call to keep track of how you’re doing. You may remain on the study as long as the treatment is still helping your disease. Study specific test will be provided at no cost to you.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT03600883

Contact= uvacancertrials@hscmail.mcc.virginia.edu

Compensation

You may receive compensation and possibly reimbursement to help with travel costs if you participate on this study.